• 1
    Whitmore WF Jr. Current therapy of bladder cancer. J Occup Med 1990; 32: 921925.
  • 2
    Zein T., Wajsman Z., Envlander LS, Gamarra M., Lopez C., Huben RP, Pontes JE. Evaluation of bladder washings and urine cytology in the diagnosis of bladder cancer and its correlation with selected biopsies of the bladder mucosa. J Urol 1984; 132: 670671.
  • 3
    Loening S., Narayama A., Yoder L., Slymen D., Weinstein S., Penick G., Culp D. Longitudinal study of bladder cancer with cytology and biopsy. Brit J Urol 1978; 50: 496501.
  • 4
    Getzenberg RH, Konety BR, Oeler TA, Quigley MM, Hakam A., Becich MJ, Bahnson RR. Bladder cancer-associated nuclear matrix proteins. Cancer Res 1996; 56: 16901694.
  • 5
    Miyanaga N., Akaza H., Ishikawa S., Ohtani M., Noguchi R., Kawai K., Koiso K., Kobayashi M., Koyama A., Takahashi T. Clinical evaluation of nuclear matrix protein 22 (NMP 22) in urine as a novel marker for urothelial cancer. Eur Urol 1997; 31: 163168.
  • 6
    Heney NM. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol Clin N Amer 1992; 19: 429433.
  • 7
    Sarosdy MF, deVere White RW, Soloway MS, Sheinfeld J., Hudson MA, Schellhammer PF, Jarowenko MV, Adams G., Blumenstein BA. Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. J Urol 1995; 154: 379383.
  • 8
    D'Hallewin M., Baert L. Initial evaluation of the bladder tumor antigen test in superficial bladder cancer. J Urol 1996; 155: 475476.
  • 9
    HermanekP., SobinLH (eds). UICC (International Union Against Cancer) TNM classification of malignant tumors. 4th ed. Heidelberg : Springer-Verlag, 1987.
  • 10
    Mostofi FK, Sobin LH, Torloni H. Histological typing of urinary bladder tumors. International Histological Classification of Tumors, No 10. Geneva : World Health Organization, 1973.
  • 11
    Bard Diagnostic Sciences Inc. BTA product package insert. 1996.